

May 30, 2018

Jorge Tuma MD
Av. Gregorio Escobedo
676 L11
Lima, Perú

Reference: Biological Therapies

Dear Dr. Tuma,

Your program to treat no option patients with adult cell therapy based on clinical trials similar to what is published in the literature is strong and supported by our team. Your team in Peru has worked very diligently and safe to provide options for patients based on your local and regional clearances and exemptions. Your group has found similar results to others that adult cell therapy is very safe and reproducible in appropriately selected patients. Hence, your team is the key group in South America we have collaborated with since 2007. You have been invited to and have presented at many international symposiums and have publications related to adult cell therapy in peer reviewed venues. Similar to your data, the other groups have found that cell therapy is safe and has promising results and is in Phase 3 in many clinical indications. The patients should be followed on a yearly basis and your work should be submitted to a peer-reviewed journal for follow up publication. There are a number of countries where adult cell therapy is approved for specific indications. It is unfortunate that there are many other groups which have not followed clinical guidelines and international practices which you and your team have strived to achieve.

If you have any questions, or need additional information, please do not hesitate to contact.

Respectfully,



Amit N. Patel MD, MS
Director of Bioinnovation
Professor of Surgery (PR)
Program Director of Thoracic Surgery
University of Miami Health System
University of Miami Hospital/Jackson Memorial
Hospital

The DeWitt Daughtry Family Department of Surgery
Cardiothoracic Surgery

1295 NW 14th Street, Suite H, Miami, FL 33125

Ph: 305-689-2780/Fax: 305-689-2865